Iovance: The Lung Selloff Went Too Far For A Business Growing 77%
Iovance’s Amtagvi revenue rose 77% to $101.6 million as a lung-data update drove a 47.6% stock drop, despite weak response rates outside a…
NASDAQ
Cap as of Nov 20 4 stories
Get IOVA news in Claude, ChatGPT or your own code. See plans
Iovance’s Amtagvi revenue rose 77% to $101.6 million as a lung-data update drove a 47.6% stock drop, despite weak response rates outside a…
Good day in the biotech basket today with $IOVA down 30% and $INSM up 15%. Reminder I have no idea what either of these companies actually do.
Hess Midstream, Iovance Biotherapeutics, Netlist and nine other lesser-covered stocks make this week’s Undercovered Dozen.
Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, with melanoma, lung cancer and international…
Companies the stories above are also about, besides IOVA.